問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Division of Hematology & Oncology

China Medical University Begiang Hospital (在職)

更新時間：2023-09-19

謝清昀Hsieh, Ching Yun
  • Principal Investigator
  • Clinical Trial Experience (year) 13 years

Recruiting Trial

84Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝清昀

List

158Cases

2018-10-01 - 2021-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting3Sites

Terminated1Sites

白禮源
China Medical University Hospital-Taipei

未分科

2026-01-15 - 2043-05-29

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-05-01 - 2028-02-29

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-03-01 - 2030-07-16

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2019-01-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-12-28 - 2022-12-31

Phase I

A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma

  • Condition/Disease

    Classical Hodgkin lymphoma (CHL), diffuse large B-cell lymphoma(DLBCL) or Peripheral T-Cell Lymphoma

  • Test Drug

    Isatuximab

Participate Sites
4Sites

Recruiting3Sites

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2017-03-01 - 2019-09-30

Phase II

Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Condition/Disease

    Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

  • Test Drug

    SP-02L

Participate Sites
6Sites

Terminated5Sites

2013-09-01 - 2019-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

  • Condition/Disease

    Diffuse Large B-Cell Lymphoma(DLBCL)

  • Test Drug

    Ibrutinib

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2017-01-15 - 2020-02-28

Phase II

An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Condition/Disease

    Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

1 9 10 11 12 13 16
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB